CGRP Treatment - Interactive Financial Assistance Guides
In 2018, a new class of medications was approved by the FDA for the prevention of migraine in adults. These drugs are referred to as calcitonin gene-related peptide (CGRP) inhibitors. There are currently three CGRP medications on the market: Aimovig™, Emgality™ and AJOVY™.
Each pharmaceutical manufacturer is offering financial assistance programs to help cover the costs of these medicines. The details for each program varies. To help you navigate, CHAMP created Financial Assistance Guides outlining the different programs.
Please note: These guides have not been produced or approved by the manufacturers. CHAMP is not endorsing the use of any CGRP inhibitor over another, nor promoting the use of this new class of preventive medications for everyone with migraine disease. Every patient needs to consult their healthcare provider to determine if CGRP inhibitors are right for you.